Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
9 min read
Tislelizumab in Large B-cell lymphoma: NCT06167785 Clinical Landscape Report 2026
16 October 2026
NCT06167785 clinical landscape for Large B-cell lymphoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Ipilimumab in Melanoma: NCT06163820 Clinical Landscape Report 2026
16 October 2026
NCT06163820 clinical landscape for Melanoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Atezolizumab in Large cell neuroendocrine carcinoma: NCT06161532 Clinical Landscape Report 2026
16 October 2026
NCT06161532 clinical landscape for Large cell neuroendocrine carcinoma: endpoints, sponsor, phase, geography, readouts, asset context and development white s…
9 min read
Recombinant oncolytic herpes simplex virus type 1(Shanghai Yunying Medical Technology) in Bone Cancer: NCT06171282 Clinical Landscape Report 2026
16 October 2026
NCT06171282 clinical landscape for Bone Cancer: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
VET2-L2 in BRAF V600E Mutation-Positive Melanoma: NCT06171178 Clinical Landscape Report 2026
16 October 2026
NCT06171178 clinical landscape for BRAF V600E Mutation-Positive Melanoma: endpoints, sponsor, phase, geography, readouts, asset context and development white…
9 min read
Enasidenib Mesylate in Large cell neuroendocrine carcinoma: NCT06176989 Clinical Landscape Report 2026
16 October 2026
NCT06176989 clinical landscape for Large cell neuroendocrine carcinoma: endpoints, sponsor, phase, geography, readouts, asset context and development white s…
9 min read
Patritumab Deruxtecan in Recurrent Cervical Cancer: NCT06172478 Clinical Landscape Report 2026
16 October 2026
NCT06172478 clinical landscape for Recurrent Cervical Cancer: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
PRO-1107 in Ovarian Cancer: NCT06171789 Clinical Landscape Report 2026
16 October 2026
NCT06171789 clinical landscape for Ovarian Cancer: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Brentuximab Vedotin in CD-30 positive Lymphoma: NCT06186986 Clinical Landscape Report 2026
16 October 2026
NCT06186986 clinical landscape for CD-30 positive Lymphoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
CD30.CAR-EBVST cell therapy(Baylor College of Medicine) in CD-30 positive Lymphoma: NCT06176690 Clinical Landscape Report 2026
16 October 2026
NCT06176690 clinical landscape for CD-30 positive Lymphoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Lenalidomide in Diffuse Large B-Cell Lymphoma: NCT06176729 Clinical Landscape Report 2026
16 October 2026
NCT06176729 clinical landscape for Diffuse Large B-Cell Lymphoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Datopotamab Deruxtecan in HER2-negative breast cancer: NCT06176261 Clinical Landscape Report 2026
16 October 2026
NCT06176261 clinical landscape for HER2-negative breast cancer: endpoints, sponsor, phase, geography, readouts, asset context and development white space.